Qiuyan Xia, Jiajia Jiang, Wei Zhao, Qi Tang, Xiaohua Li, Tengqi Wang, Yan Zhou. Epiregulin promotes growth and metastasis of gastric cancer via the ERK/JNK/p38 signaling pathway[J]. Blood&Genomics, 2021, 5(2): 135-145. DOI: 10.46701/BG.2021022021125
Citation: Qiuyan Xia, Jiajia Jiang, Wei Zhao, Qi Tang, Xiaohua Li, Tengqi Wang, Yan Zhou. Epiregulin promotes growth and metastasis of gastric cancer via the ERK/JNK/p38 signaling pathway[J]. Blood&Genomics, 2021, 5(2): 135-145. DOI: 10.46701/BG.2021022021125

Epiregulin promotes growth and metastasis of gastric cancer via the ERK/JNK/p38 signaling pathway

  • Epiregulin (EREG) is a ligand of the epidermal growth factor receptor. It belongs to the ErbB family of ligands found overexpressed in various cancers such as colon cancer and lung carcinoma and is likely to play diverse oncogenic roles in several other cancer types. However, little is known about the mechanisms of EREG in the pathogenesis of gastric cancer (GC). The present study was undertaken to investigate whether EREG influences the development and progression in GC. The results revealed that EREG was found to be overexpressed in human GC cells lines. Moreover, EREG induced cell migration, invasion, and proliferation, and inhibited apoptosis in vitro. The study also found that EREG depletion inhibited tumor growth in vivo. Our findings indicated that EREG activated the ERK/JNK/p38 signaling pathway and PI3K/Akt signaling pathways to promote GC malignant progression. Overall, this study suggests that EREG may promote GC development and progression through the ERK/JNK/p38 and PI3K/Akt signaling pathways, which may improve our understanding of the molecular mechanism of EREG in GC. Thus, EREG may be a potential target for GC treatment.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return